2534-90-9

Upstream product

• 934-28-1 bicyclo(2.2.1)heptane-2-endo-carboxylic acid 
• 934-29-2 acide bicyclo<2.2.1>heptane carboxylique-2 exo 
• 2534-71-6 (+/-)-2-bromo-norbornane-2endo-carboxylic acid 
• 934-28-1 norbornane-2-carboxylic acid 
• 18720-30-4 norbornane-1-carboxylic acid 
• 1755-01-7 endo-Dicyclopentadien 
• 61242-71-5 (1R,2S,4S)-Bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 51789-95-8 bicyclo[2.2.1]hept-5-ene-endo-2-carboxylic acid ethyl ester 
• 19926-90-0 (+/-)-endo-bicyclo[2.2.1]hept-5-ene-2-carbaldehyde 
• 3574-54-7 2-endo-Bicyclo<2.2.1>heptanecarboxaldehyde 
• 100379-07-5 2-exo-Bromobicyclo<2.2.1>heptane-2-endo-carboxaldehyde 

Downstream Products

• 41248-20-8 (+/-)-2-hydroxy-norbornane-2endo-carboxylic acid 
• 104085-12-3 (1S,2S,4R)-2-Bromo-bicyclo[2.2.1]heptane-1-carboxylic acid ((R)-2-hydroxy-1-phenyl-ethyl)-amide 
• 104085-11-2 (1R,2R,4S)-2-Bromo-bicyclo[2.2.1]heptane-1-carboxylic acid ((R)-2-hydroxy-1-phenyl-ethyl)-amide 
• 149891-94-1 bicyclo<2.2.2>octane-1-carboxaldehyde-d tosylhydrazone 
• 7363-97-5 bicyclo<2.2.2>octane-1-carboxaldehyde tosylhydrazone 
• 2574-42-7 bicyclo<2.2.2>octane-1-methanol 
• 699-55-8 bicyclo[2.2.2]octane-1-carboxylic acid 
• 18720-30-4 norbornane-1-carboxylic acid 
• 2287-57-2 methyl bicyclo<2.2.1>heptane-1-carboxylate 
• 104085-16-7 (1S,2S,4R)-2-Bromo-bicyclo[2.2.1]heptane-1-carboxylic acid (R)-2-amino-2-phenyl-ethyl ester 
• 104085-15-6 (1R,2R,4S)-2-Bromo-bicyclo[2.2.1]heptane-1-carboxylic acid (R)-2-amino-2-phenyl-ethyl ester 
• 104085-13-4 (R)-2-((1R,2R,4S)-2-Bromo-bicyclo[2.2.1]hept-1-yl)-4-phenyl-4,5-dihydro-oxazole 
• 104085-14-5 (R)-2-((1S,2S,4R)-2-Bromo-bicyclo[2.2.1]hept-1-yl)-4-phenyl-4,5-dihydro-oxazole 
• 2534-77-2 exo-2-bromonorbornane 

Relevant academic research and scientific papers

Protected amino hydroxy adamantane carboxylic acid and process for its preparation

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided. The provided compounds can be used for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.

From norbornane-based nucleotide analogs locked in South conformation to novel inhibitors of feline herpes virus

A synthetic route toward a series of unique cyclic nucleoside phosphonates locked in South conformation is described. The desired conformation is stabilized by a substitution of the sugar moiety by bicyclo[2.2.1]heptane (norbornane) bearing a purine or pyrimidine nucleobase in the bridgehead position. Although the final phosphonate derivatives are devoid of any significant antiviral activity probably due to the unfavorable conformational properties, several intermediates and their analogs exhibit surprising activity against feline herpes virus. Since these compounds do not possess an appropriate hydroxymethyl function allowing phosphorylation and subsequent incorporation into the polynucleotide chain, it seems to be likely that these compounds act by a novel unknown mechanism of action and may represent a new possible alternative for nucleoside and nucleotide therapeutics of this widely spread feline infection. A number of derivatives exerted also a significant antiviral activity against Coxsackievirus B3 and B4.

Bicyclonon-1-ene: Matrix Isolation and Spectroscopic Characterization of a Moderately Strained Bridgehead Olefin

Bicyclonon-1-ene was generated in low-temperature matrices and in fluid solutions by photodecomposition of bicyclooct-1-yldiazomethane and its photorearrangement product, 3-(bicyclooct-1-yl)diazirine.It was characterized by IR and UV absorption and by 1H and 13C NMR spectroscopy.Further evidence for the proposed structure was provided by self-trapping and by the spectral effects of deuteration on the olefinic carbon.Observed IR spectra and isotopic shifts agree well with the results of semiempirical (MNDO) and ab initio (SCF/6-31G*) calculations.